![](https://pharmasource.global/wp-content/uploads/2024/04/Lonza-1.png)
Lonza has appointed Wolfgang Wienand as Chief Executive Officer, to join the company during the summer of 2024.
Wolfgang currently holds the position of CEO at the Swiss contract development and manufacturing organization (CDMO) Siegfried Holding AG, a role he has held since 2019. Prior to this, Wolfgang served as Chief Scientific Officer and then as Chief Strategy Officer in Siegfried’s executive leadership team. Before joining Siegfried in 2010, Wolfgang held a series of increasingly senior positions at the German specialty chemicals company Evonik Industries.
Albert M. Baehny, Chairman of the Board of Directors and interim CEO at Lonza, expressed his satisfaction with the appointment, stating, “The Board is delighted to have selected a seasoned CEO with a strong and established track record of success in the CDMO industry. Wolfgang brings a wealth of knowledge and experience to Lonza, complemented by his deep scientific and strategic expertise. With his proven leadership capabilities, Wolfgang is ideally positioned to represent our business and guide our colleague community as Lonza embarks on the next phase of its growth journey.”
Meanwhile, the Board of Directors of Siegfried has appointed CFO Reto Suter as interim CEO. He will assume this additional responsibility as of May 1st, 2024. The search for the new Siegfried CEO has been initiated.